Short Interest in Grifols, S.A. (NASDAQ:GRFS) Decreases By 8.5%

Grifols, S.A. (NASDAQ:GRFS) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totalling 5,060,000 shares, a decline of 8.5% from the August 31st total of 5,530,000 shares. Based on an average daily trading volume, of 1,730,000 shares, the days-to-cover ratio is presently 2.9 days. Approximately 2.0% of the company’s shares are short sold.

Grifols Trading Down 0.6 %

Shares of GRFS stock traded down $0.05 during trading hours on Tuesday, hitting $8.83. 561,497 shares of the company were exchanged, compared to its average volume of 2,075,411. The company has a 50 day simple moving average of $8.25 and a two-hundred day simple moving average of $7.46. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.80 and a current ratio of 1.68. Grifols has a fifty-two week low of $5.30 and a fifty-two week high of $12.15.

Grifols (NASDAQ:GRFS) last posted its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). Grifols had a return on equity of 1.73% and a net margin of 0.90%. The company had revenue of $1.96 billion during the quarter. On average, research analysts forecast that Grifols will post 0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Grifols in the fourth quarter valued at approximately $26,137,000. Campbell & CO Investment Adviser LLC bought a new stake in Grifols in the 4th quarter valued at about $610,000. First Trust Advisors LP lifted its holdings in Grifols by 6.9% during the fourth quarter. First Trust Advisors LP now owns 4,684,749 shares of the biotechnology company’s stock valued at $54,156,000 after purchasing an additional 302,380 shares during the last quarter. Capital International Sarl boosted its position in Grifols by 11.1% during the fourth quarter. Capital International Sarl now owns 388,824 shares of the biotechnology company’s stock worth $4,495,000 after purchasing an additional 38,818 shares during the period. Finally, Capital World Investors increased its stake in shares of Grifols by 0.8% in the fourth quarter. Capital World Investors now owns 19,787,525 shares of the biotechnology company’s stock worth $228,744,000 after purchasing an additional 158,474 shares in the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.